History
Please select your profile

Suche

About ous History

  • 1992 - 2001

    • 1992
      • Foundation of Medical Strategy GmbH by Dr. Michael Fischer
    • 1998

      • Permission to operate financial portfolio management by the German Federal Banking Supervisory Office (BaKred, now BaFin)

      • Takeover of the first fund mandate

    • 2000

      • Initiation and launch of MEDICAL BioHealth, start of partnership with Oppenheim Asset Management in Luxembourg.

      • Harald Schwarz and Jürgen Harter join Medical Strategy

    • 2001
      • Fund of the Year" awarded for the first time by FINANZEN magazine

  • 2004 - 2014

    • 2004

      • MEDICAL BioHealth receives AA rating from Standard & Poor's for the first time

      • Dr. Michael Fischer receives three gold medals for the first time from Sauren Fonds Research

    • 2005
      • Initiation and launch of apo Medical Opportunities, fund management for approx. 50% of the fund volume. Start of partnership with apo asset, a subsidiary of Deutsche Apotheker- und Ärztebank.
    • 2006
      • Awarding of the Lipper Fund Award for MEDICAL BioHealth
    • 2009
      • Awarding of the Sauren Golden Award to Dr. Michael Fischer
    • 2010

      • First award of the Long-Term Fund Management Rating (5 year) by Standard & Poor's for MEDICAL BioHealth

      • 10th anniversary of MEDICAL BioHealth

    • 2011
      • First award of Gold Fund Grading and 5-year Long-Term Grading by S&P Capital IQ for MEDICAL BioHealth
    • 2014
      • Launch of apo Medical Opportunities Institutional, fund management for approx. 50% of the fund volume

  • 2017 - 2021

    • 2017

      • Investment Advisory (as of 01.09.17 Fund Management) of RIM GLOBAL BIOSCIENCE.

      • Mario Linimeier is appointed Managing Director

    • 2018

      • Medical Strategy is awarded the FinanzResearch AWARD. In the field of independent asset managers in Germany, the company was rated "Outstanding".

      • At the "Funds Europe Awards" in London, Medical Strategy is awarded a special recommendation in the category "European Specialized Investment Company of the Year".

    • 2019
      • Apo Asset Management (apoAsset) acquires a stake in Medical Strategy.
    • 2020

      • Medical Strategy receives seven Euro Fund Awards for MEDICAL BioHealth and RIM Global Bioscience

      • Katrin Winterstein appointed authorized signatory

    • 2021
      • Medical Strategy receives nine Euro Fund Awards for MEDICAL BioHealth and RIM Global Bioscience